Sino Biopharmaceutical Limited

PINK:SBMFF USA Biotechnology
Market Cap
$8.12 Billion
Market Cap Rank
#3279 Global
#2180 in USA
Share Price
$0.45
Change (1 day)
+0.00%
52-Week Range
$0.42 - $0.45
All Time High
$1.29
Categories
Companies in USA Biotechnology
About

Sino Biopharmaceutical Limited, an investment holding company, operates as a research and development pharmaceutical conglomerate in the People's Republic of China. It operates through three segments: Modernised Chinese Medicines and Chemical Medicines, Investment, and Others. The company offers oncology medicines, including anlotinib hydrochloride capsules under Focus V brand, penpulimab injecti… Read more

Sino Biopharmaceutical Limited (SBMFF) - Net Assets

Latest net assets as of June 2025: $45.78 Billion USD

Based on the latest financial reports, Sino Biopharmaceutical Limited (SBMFF) has net assets worth $45.78 Billion USD as of June 2025.

Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets ($74.89 Billion) and total liabilities ($29.12 Billion). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.

Key Net Assets Metrics

Metric Value
Current Net Assets $45.78 Billion
% of Total Assets 61.12%
Annual Growth Rate 25.49%
5-Year Change 90.79%
10-Year Change 389.14%
Growth Volatility 52.13

Sino Biopharmaceutical Limited - Net Assets Trend (1999–2024)

This chart illustrates how Sino Biopharmaceutical Limited's net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.

Annual Net Assets for Sino Biopharmaceutical Limited (1999–2024)

The table below shows the annual net assets of Sino Biopharmaceutical Limited from 1999 to 2024.

Year Net Assets Change
2024-12-31 $42.77 Billion +12.06%
2023-12-31 $38.17 Billion +0.60%
2022-12-31 $37.94 Billion +0.57%
2021-12-31 $37.73 Billion +68.29%
2020-12-31 $22.42 Billion -44.35%
2019-12-31 $40.28 Billion +7.28%
2018-12-31 $37.55 Billion +197.75%
2017-12-31 $12.61 Billion +17.98%
2016-12-31 $10.69 Billion +22.24%
2015-12-31 $8.74 Billion +24.01%
2014-12-31 $7.05 Billion +24.90%
2013-12-31 $5.65 Billion +21.21%
2012-12-31 $4.66 Billion +20.49%
2011-12-31 $3.87 Billion +5.45%
2010-12-31 $3.67 Billion +37.51%
2009-12-31 $2.67 Billion +14.17%
2008-12-31 $2.34 Billion +12.26%
2007-12-31 $2.08 Billion +2.11%
2006-12-31 $2.04 Billion -0.93%
2005-12-31 $2.06 Billion +187.80%
2004-12-31 $714.41 Million +35.00%
2003-12-31 $529.20 Million +18.02%
2002-12-31 $448.41 Million +23.79%
2001-12-31 $362.24 Million +43.79%
2000-12-31 $251.92 Million +72.10%
1999-12-31 $146.38 Million --

Equity Component Analysis

This analysis shows how different components contribute to Sino Biopharmaceutical Limited's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.

Equity Composition Insights

  • Retained earnings have grown by 2528056000000.0% over the analyzed period, indicating profitable operations and earnings retention.

Current Equity Component Breakdown (December 2024)

Component Amount Percentage
Retained Earnings $25.28 Billion 79.10%
Common Stock $414.38 Million 1.30%
Other Components $6.27 Billion 19.60%
Total Equity $31.96 Billion 100.00%

Sino Biopharmaceutical Limited Competitors by Market Cap

The table below lists competitors of Sino Biopharmaceutical Limited ranked by their market capitalization.

Company Market Cap
IES Holdings Inc
NASDAQ:IESC
 		$4.00 Billion
SG Micro Corp
SHE:300661
 		$4.00 Billion
Shenghe Resources Holding Co Ltd
SHG:600392
 		$4.00 Billion
St Galler Kantonalbank AG
SW:SGKN
 		$4.00 Billion
Polycab India Limited
NSE:POLYCAB
 		$4.00 Billion
Japan Metropolitan Fund Investment Corporation
OTCGREY:JRFIF
 		$3.99 Billion
Powertech Technology Inc
TW:6239
 		$3.99 Billion
John Bean Technologies Corporation
NYSE:JBT
 		$3.99 Billion

Equity Growth Attribution

This analysis shows how different factors contributed to changes in Sino Biopharmaceutical Limited's equity between the two most recent reporting periods.

Equity Growth Insights

  • From 2023 to 2024, total equity changed from 30,474,469,000 to 31,960,789,000, a change of 1,486,320,000 (4.9%).
  • Net income of 3,499,834,000 contributed positively to equity growth.
  • Dividend payments of 1,846,381,000 reduced retained earnings.
  • Share repurchases of 1,252,200,000 reduced equity.
  • New share issuances of 150,674,000 increased equity.
  • Other comprehensive income increased equity by 9,948,506,000.
  • Other factors decreased equity by 9,014,113,000.

Equity Change Factors (2023 to 2024)

Factor Impact Contribution
Net Income $3.50 Billion +10.95%
Dividends Paid $1.85 Billion -5.78%
Share Repurchases $1.25 Billion -3.92%
Share Issuances $150.67 Million +0.47%
Other Comprehensive Income $9.95 Billion +31.13%
Other Changes $-9.01 Billion -28.2%
Total Change $- 4.88%

Book Value vs Market Value Analysis

This analysis compares Sino Biopharmaceutical Limited's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.

Valuation Insights

  • Current price-to-book ratio: 0.26x
  • The company is trading below its book value, potentially indicating the market believes the assets are overvalued on the balance sheet or anticipates future losses.
  • The price-to-book ratio has decreased from 9.98x to 0.26x over the analyzed period, indicating reduced market premium.

Historical Price-to-Book Ratios

Date Book Value per Share Market Price P/B Ratio
1999-12-31 $0.05 $0.45 x
2000-12-31 $0.08 $0.45 x
2001-12-31 $0.08 $0.45 x
2002-12-31 $0.09 $0.45 x
2003-12-31 $0.02 $0.45 x
2004-12-31 $0.03 $0.45 x
2005-12-31 $0.13 $0.45 x
2006-12-31 $0.13 $0.45 x
2007-12-31 $0.12 $0.45 x
2008-12-31 $0.13 $0.45 x
2009-12-31 $0.14 $0.45 x
2010-12-31 $0.19 $0.45 x
2011-12-31 $0.19 $0.45 x
2012-12-31 $0.22 $0.45 x
2013-12-31 $0.26 $0.45 x
2014-12-31 $0.32 $0.45 x
2015-12-31 $0.39 $0.45 x
2016-12-31 $0.48 $0.45 x
2017-12-31 $0.55 $0.45 x
2018-12-31 $1.57 $0.45 x
2019-12-31 $1.65 $0.45 x
2020-12-31 $0.89 $0.45 x
2021-12-31 $1.57 $0.45 x
2022-12-31 $1.56 $0.45 x
2023-12-31 $1.64 $0.45 x
2024-12-31 $1.75 $0.45 x

Capital Efficiency Dashboard

This dashboard shows how efficiently Sino Biopharmaceutical Limited utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.

Capital Efficiency Insights

  • Current Return on Equity (ROE): 10.95%
  • The company shows good efficiency in utilizing shareholder equity.
  • DuPont Analysis Breakdown:
  • • Net Profit Margin: 12.12%
  • • Asset Turnover: 0.44x
  • • Equity Multiplier: 2.05x
  • Recent ROE (10.95%) is below the historical average (22.88%), suggesting potential challenges in capital efficiency.

Historical Capital Efficiency Metrics

Year Return on Equity Net Profit Margin Asset Turnover Equity Multiplier Economic Value Added
1999 34.45% 11.72% 1.13x 2.60x $27.08 Million
2000 22.82% 11.58% 1.03x 1.91x $27.11 Million
2001 25.25% 11.43% 1.25x 1.77x $39.56 Million
2002 19.59% 8.29% 1.17x 2.03x $29.81 Million
2003 24.01% 9.93% 1.12x 2.16x $50.77 Million
2004 36.79% 16.03% 1.14x 2.01x $130.59 Million
2005 89.17% 218.58% 0.35x 1.15x $1.53 Billion
2006 7.40% 19.22% 0.33x 1.16x $-49.82 Million
2007 11.11% 19.27% 0.45x 1.29x $21.01 Million
2008 13.35% 13.04% 0.70x 1.47x $65.79 Million
2009 16.04% 12.24% 0.86x 1.52x $131.65 Million
2010 15.54% 13.87% 0.73x 1.54x $172.26 Million
2011 12.06% 8.00% 0.92x 1.64x $64.10 Million
2012 19.44% 10.70% 1.07x 1.71x $348.29 Million
2013 18.89% 10.47% 0.99x 1.82x $381.38 Million
2014 22.89% 12.22% 0.87x 2.14x $681.41 Million
2015 22.93% 12.22% 0.88x 2.13x $839.98 Million
2016 21.53% 12.09% 0.77x 2.31x $917.61 Million
2017 23.57% 14.65% 0.71x 2.27x $1.25 Billion
2018 30.97% 43.31% 0.42x 1.70x $6.13 Billion
2019 15.09% 19.37% 0.42x 1.87x $1.58 Billion
2020 16.55% 11.72% 0.50x 2.82x $1.10 Billion
2021 48.23% 54.38% 0.44x 2.00x $11.58 Billion
2022 8.55% 9.77% 0.41x 2.15x $-431.13 Million
2023 7.65% 8.90% 0.41x 2.09x $-715.51 Million
2024 10.95% 12.12% 0.44x 2.05x $303.76 Million

Industry Comparison

This section compares Sino Biopharmaceutical Limited's net assets metrics with peer companies in the Biotechnology industry.

Industry Context

  • Industry: Biotechnology
  • Average net assets among peers: $59,082,939
  • Average return on equity (ROE) among peers: -341.19%

Peer Company Comparison

Company Net Assets Return on Equity Debt-to-Equity Market Cap
Sino Biopharmaceutical Limited (SBMFF) $45.78 Billion 34.45% 0.64x $4.00 Billion
Aadi Bioscience Inc (AADI) $-124.24K 0.00% 0.00x $17.03 Million
America Great Health (AAGH) $-992.37K 0.00% 0.00x $2.12 Million
Ascentage Pharma Group International (AAPG) $70.63 Million -1310.51% 34.40x $2.25 Billion
Aardvark Therapeutics, Inc. Common Stock (AARD) $-27.92 Million 0.00% 0.00x $59.18 Million
ABIVAX Société Anonyme (AAVXF) $196.01 Million -75.37% 0.67x $377.86 Million
Abcellera Biologics Inc (ABCL) $10.25 Million -21.57% 1.29x $738.02 Million
Abeona Therapeutics Inc (ABEO) $489.00K -1919.02% 38.85x $202.79 Million
Acumen Pharmaceuticals Inc (ABOS) $188.78 Million -22.70% 0.04x $108.65 Million
Abpro Holdings, Inc. (ABP) $-22.46 Million 0.00% 0.00x $2.00 Million
Absci Corp (ABSI) $176.18 Million -62.76% 0.23x $345.85 Million